Loading clinical trials...

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06706557

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer

A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)

Lead sponsor: European Institute of Oncology•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Nicola Fusco, MD

CONTACT

00390294372079 [email protected]

francesca lombardi, biologist

CONTACT

00390257489425 [email protected]

Related studies

COMPLETEDPhase 1

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388 · Advanced Metastatic Breast Cancer

COMPLETEDPhase 2

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

NCT01231659 · Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 26, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment30

Start dateJan 2024

Last updatedNov 26, 2024

Condition

Advanced Metastatic Breast Cancer

Locations shown

European Institute of Oncology

Milan, MI

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 26, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions